Depression, Suicidal Ideation
Conditions
Keywords
genetic markers, predictors, Antidepressive Agents, Suicidal Ideation, Adolescent
Brief summary
The objective of this study is to identification of genetic markers and predictors of antidepressant-induced suicidality in youth depression. Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. They will do several scales and genetic tests at visit 1 (week 0), visit 3 (week 4) and visit 4 (week 8)
Interventions
DRUGbupropion or lamotrigine
Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
11 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Aged between 11 and 18 years 2. Met the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL) diagnostic criteria for depressive episode or dysthymia 3. Intelligence quotient higher than 70 on the Korean Educational Developmental Institute's Wechsler Intelligence Scale for Children
Exclusion criteria
1. presence of intellectual disability 2. presence of hereditary disorder 3. past and/or current history of acquired brain injury, like cerebral palsy 4. presence of seizure, other neurological disorder or sensory impairments 5. past and/or current history of pervasive developmental disorder 6. past and/or current history of schizophrenia, bipolar disorder or psychosis 7. presence of severe learning disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Suicidal ideation and behavior | 8 weeks | Using Columbia-Suicide Severity Rating Scale(C-SSRS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of treatment effect of antidepressants(CDRS) | 8 weeks | A composite measure consisting of Children's Depression Rating scale(CDRS). Modeled after the Hamilton Rating Scale for Depression, the CDRS is a clinical interview tool designed for assessing 6-12 year-olds, and it has also been used successfully for adolescents. |
| Evaluation of treatment effect of antidepressants (YMRS) | 8 weeks | A composite measure consisting of Young Mania Rating Scale(YMRS). The YMRS is an 11-item scale used to assess the severity of mania in children and adolescents ages 5-17.The YMRS has been used in clinical practice since 1978. Ratings are based on child/adolescent self-reporting and clinician observation. This instrument does not assess depressed mood. |
| Evaluation of treatment effect of antidepressants(P-GBI) | 8 weeks | The P-GBI is adapted from the General Behavior Inventory, and allows parents to rate depressive, hypomanic, manic, and alternating mood symptoms in their children and adolescents ages 5-17. |
| Evaluation of treatment effect of antidepressants(CGI-S) | 8 weeks | The Clinical Global Impression rating scales(CGI-S) are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. |
| Genome wide association analysis | 8 weeks | KNIH Biobank Array |
Countries
South Korea
Contacts
Primary Contactlee myungeun, BA
Backup ContactSojung Park, BA
Outcome results
None listed